Dementia and Alzheimer Disease

The trial will use PACC-5 score as its primary end point and expects to enroll 1200 participants who have confirmed amyloid pathology without signs of cognitive impairment.

The treatment is being developed as a first-in-class regenerative therapy for those with AD and dementia, with these safety data offering support to its development.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 25, 2022.

The director of Geriatric Psychiatry at the St Louis University School of Medicine discussed the need to improve awareness of the signs of psychiatric-related symptoms and to eliminate the stigmas associated with them. [WATCH TIME: 3 minutes]

The resubmission includes additional data from the phase 2 Study -019 and the pivotal phase 3 HARMONY study, which showed a significant 2.8-fold reduction in the risk of relapse of psychosis.

The Samuel W. Fordyce professor and director of Geriatric Psychiatry at the St Louis University School of Medicine discussed the critical roles specialists and caregivers during telehealth visits in long-term care settings. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

The director of Geriatric Psychiatry at the St Louis University School of Medicine discussed what clinicians should pay attention to when conducting telehealth visits for psychosis-related symptoms in patients with neurodegenerative diseases. [WATCH TIME: 3 minutes]

Imad Najm, MD, provided commentary on the long-term efforts needed to understand the origins of neurological brain diseases and his desire to copy the success of the cardiovascular field.

Neurology News Network for the week ending February 19, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 18, 2022.

The director of Cleveland Clinic’s Epilepsy Center discussed the currently known overlap between neurological diseases and the need to identify causative biomarkers. [WATCH TIME: 4 minutes]

Slightly over one-fourth of the surveyed cohort who were concerned about Alzheimer disease reported “some” or a “fair amount” of knowledge of aducanumab (Aduhelm; Biogen).

With the physician deficit projected to grow larger within a decade, this global challenge has become a major focus of large organizations and medical societies.

Among participants with high sleep efficiency, those who received transcranial direct current stimulation benefitted more from language therapy than those who received sham, whereas those with low sleep efficiency demonstrated no additional benefit.

The Samuel W. Fordyce professor and director of Geriatric Psychiatry at the St Louis University School of Medicine provided insight on critical aspects of telehealth use for assessing and managing psychosis in patients with neurodegenerative diseases.

At week 10 of this interim analysis, treatment with high-dose ACI-35.030 showed no new safety signals and boosted median levels of antibodies reactive with pathological tau.

Biogen proposed a 3-prong approach to generate ‘real-world evidence’ and answer remaining questions from CMS.

The Samuel W. Fordyce professor and director of Geriatric Psychiatry at the St. Louis University School of Medicine discussed the motivation behind recently published recommendations for clinicians who treat psychosis in neurodegenerative diseases in a telemedicine setting. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending February 12, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 11, 2022.

The director of Cleveland Clinic’s Epilepsy Center provided insight on a new 20-year initiative to uncover more about the origins of neurological diseases and how they occur prior to symptom onset. [WATCH TIME: 3 minutes]

The director of Cleveland Clinic’s Epilepsy Center discussed the new Cleveland Clinic Brain Study, which will evaluate predisease fingerprints from patients who go on to develop neurological disorders.

Alireza Atri, MD, PhD, concludes with a discussion on how different testing methods impact the care of patients with AD.

Dr Atri continues his discussion on aducanumab and AD diagnostic evaluations.

Dr Atri explains how aducanumab plays a role in diagnostic evaluations for patients with AD.

The cognitive neurologist at the University of California San Francisco discussed the need to continue research on why patients develop cognitive changes following COVID-19 infection and how clinicians can care for them. [WATCH TIME: 4 minutes]

In previous phase 1 settings, CY6463 has demonstrated an impact on biomarkers relevant to neurodegeneration and cognitive impairment.